Merck faces ongoing claims after Texan ruling on rofecoxibBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7515.471 (Published 01 September 2005) Cite this as: BMJ 2005;331:471
- Janice Hopkins Tanne
- New York
The drug company Merck may face thousands of lawsuits over its cyclo-oxygenase-2 inhibitor rofecoxib (Vioxx) after losing a court case concerning the death from an arrhythmia of a fit 59 year old man from Texas who was taking the drug. The jury awarded his widow $253.4m (£140m; €206m)—$24.4m for economic loss and emotional anguish and $229m in punitive damages. However, the award will be reduced under Texan law to about $26m. Merck has said it will appeal.
But Merck faces at least 4200 state and federal lawsuits in the United States by people or their relatives who say they were harmed by the drug.
People elsewhere—the United Kingdom and other European countries, Australia, New Zealand, Israel, and Brazil—are …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial